Get startedLog in
    Picture of Madrigal Pharmaceuticals logo

    MDGL — Madrigal Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

    Picture of Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals
    10/05/2025 12:19
    May 10 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:

MADRIGAL ANNOUNCES NEW CLINICAL DATA DEMONSTRATING REZDIFFRA™ (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE TESTS AND PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS

MADRIGAL PHARMACEUTICALS INC - PATIENTS ACHIEVED 6.7 KPA REDUCTION IN LIVER STIFFNESS

MADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATE

MADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWO

Source text: ID:nGNX1DmCGG

Further company coverage: MDGL.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Madrigal Pharmaceuticals

    See all news